Trial Information

Summary: Multiple Myeloma Study CLBH589B2206

Novartis Oncology is conducting this clinical trial to find out the effects, both positive and negative, of a study drug called LBH589 when administered together with oral lenalidomide and dexamethasone to people who have a form of bone marrow cancer called Multiple Myeloma that has not responded to prior treatments. The study drug LBH589 is being tested as part of this study and is currently not available for purchase on the market in any country.

Participants will be required to take 3 drugs over a 28 day period. They will take oral LBH589 once-a-day on Monday, Wednesday, and Friday each week. In addition, they will take lenalidomide once-a-day, and dexamethasone once-a-day on specific days during the 28 day treatment cycle. Participants will be asked to come to the clinic one to four times each week. Each of these visits should take about 1-3 hours, but there are a few visits that may take up to 8 hours.

For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 22, 2008 at 2:59:23 PM